Coherus Reports the Divestment of Yusimry (Biosimilar, Humira) to Hong Kong King-Friend Industry
Shots:
- Coherus has divested Yusimry under an asset purchase agreement to Hong Kong King-Friend Industry (HKF) granting it global rights & all relevant assets of Yusimry such as its development & regulatory outcomes for $40M upfront
- HKF has further granted the US commercial rights of the asset to Meitheal Pharmaceuticals (its subsidiary) under an exclusive license & supply agreement. Both the agreements will be effective, pending standard conditions & approvals
- Meitheal will develop pediatric presentations & a high-concentration (100mg/mL) formulation of Yusimry (available in prefilled syringe & autoinjector forms), with its approvals in other indications & formulation anticipated in 2025
Ref: Businesswire | Image: Coherus
Related News:- Coherus Launches Yusimry (biosimilar, adalimumab) in the US at 85% Discount
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
